RecruitingNot ApplicableNCT05562960
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Sponsor
National Taiwan University Hospital
Enrollment
20 participants
Start Date
May 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody
Eligibility
Min Age: 20 Years
Inclusion Criteria3
- Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.
- Agree to receive plasmapheresis intervention.
- Agree to participate in the trial and receive serial examinations and follow up.
Exclusion Criteria6
- Patients without plasma anti-NRIP autoantibody.
- Patients requiring permanent ventilator support for ALS progression.
- Not able to receive plasmapheresis or trial-related examinations.
- Under pregnancy.
- Blood fibrinogen level less than 50 mg/dl.
- Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREPlasmapheresis
Regular plasmapheresis to remove anti-NRIP autoantibody
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05562960
Related Trials
Multicenter ALS Imaging Study
NCT067350143 locations
Breathing With Amyotrophic Lateral Sclerosis
NCT058199311 location
HEALEY ALS Platform Trial - Master Protocol
NCT0429768378 locations
Ultra-high-caloric, Fatty Diet in ALS
NCT0628007923 locations
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
NCT067265771 location